Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HTRA1 is a secreted serine protease enzyme involved in extracellular matrix remodeling, TGF-beta regulation, and protein quality control. It functions as a homotrimer and its dysregulation is implicated in CARASIL, age-related macular degeneration, osteoarthritis, Alzheimer’s disease, and cancer. It presents both potential benefits and challenges as a therapeutic target. Inhibiting HTRA1 might promote TGF-beta signaling, which could have variable effects depending on the context (e.g., promoting fibrosis in some cases). Conversely, enhancing HTRA1 activity could potentially be beneficial in Alzheimer's by promoting tau aggregate degradation but may disrupt normal tissue remodeling. Careful consideration of tissue-specific effects and potential off-target activities would be essential in developing HTRA1-targeted therapies.
Serine protease inhibitor (potential)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High-temperature requirement A serine peptidase 1 (HTRA1).